Head-to-head · Cost-Efficiency Index
REMEVi vs Vaylen
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
REMEVi
Cost-first shoppers who want bilingual, LegitScript-certified compounded GLP-1.
Visit REMEViVaylen
Cost-first shoppers who want gLP-1-focused care with oral and injectable options across all 50 states.
Visit VaylenThe verdict
REMEVi and Vaylen tie on the Cost-Efficiency Index at 80/100, so neither wins outright on the numbers. For most shoppers we'd start with REMEVi (ranked #33, a hair above #34) — Cost-first shoppers who want bilingual, LegitScript-certified compounded GLP-1. But Vaylen is a genuine coin-flip alternative here.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs REMEVi.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | REMEVi | Vaylen |
|---|---|---|
| Cost-Efficiency Index | 80/100 | 80/100 |
| Semaglutide / mo | $219/mo | $179/mo (compounded) |
| Tirzepatide / mo | $319/mo | $239/mo (compounded) |
| Semaglutide / yr (modeled) | $2,628 | $2,148 |
| Tirzepatide / yr (modeled) | $3,828 | $2,868 |
| Coverage | All 50 states | All 50 states |
| Oral / sublingual | Yes | Yes |
| Brand-name access | Compounded only | Yes |
| Rank here | #33 | #34 |
REMEVi
80/100Where the value is
- A genuinely flat rate: 'the same price at every dose', stated as such, with no dose upcharge and no introductory rate to step off
- Longer terms are published openly rather than used as a teaser — semaglutide falls to $189 on 12 weeks and $149 on 52
- A daily oral semaglutide tablet is offered alongside the injection
The tradeoffs
- The flat rate is the highest entry price of the top-scoring programs here; the cheaper $149 figure needs a full year
- No FDA-approved brand-name pathway — the Wegovy and Ozempic pages are comparison content, not products
Vaylen
80/100Where the value is
- Pure GLP-1 specialist — not a multi-category telehealth platform
- All 50 states coverage with licensed clinicians
- Both compounded and brand-name options (Ozempic, Wegovy, Zepbound)
The tradeoffs
- Compounded semaglutide at $179/mo is mid-range (not the cheapest)
- Brand-name options at near-retail pricing ($997-$1,086/mo)
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.